Complete financial analysis of Ensysce Biosciences, Inc. (ENSC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ensysce Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- The Real Good Food Company, Inc. (RGF) Income Statement Analysis – Financial Results
- Ginza Renoir Co., Ltd. (9853.T) Income Statement Analysis – Financial Results
- Canopy Growth Corporation (CGC) Income Statement Analysis – Financial Results
- ST Energy Transition I Ltd. (STET-WT) Income Statement Analysis – Financial Results
- PD-Rx Pharmaceuticals, Inc. (PDRX) Income Statement Analysis – Financial Results
Ensysce Biosciences, Inc. (ENSC)
About Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.23M | 2.52M | 3.53M | 3.93M | 1.76M | 0.00 | 0.00 |
| Cost of Revenue | 7.59M | 19.84M | 151.00 | 1.37M | 3.33M | 1.56M | 0.00 |
| Gross Profit | -5.36M | -17.31M | 3.53M | 2.56M | -1.56M | -1.56M | 0.00 |
| Gross Profit Ratio | -240.17% | -686.08% | 100.00% | 65.18% | -88.70% | 0.00% | 0.00% |
| Research & Development | 7.59M | 19.84M | 4.69M | 4.39M | 3.40M | 0.00 | 0.00 |
| General & Administrative | 5.36M | 6.91M | 18.71M | 1.15M | 6.93M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -3.60M | 0.00 | 0.00 |
| SG&A | 5.36M | 6.91M | 18.71M | 1.15M | 3.33M | 1.56M | 146.70K |
| Other Expenses | -7.59M | -2.52M | -3.53M | -3.93M | 0.00 | 600.00K | 0.00 |
| Operating Expenses | 5.36M | 24.22M | 19.87M | 1.61M | 3.33M | 959.25K | 146.70K |
| Cost & Expenses | 12.95M | 24.22M | 19.87M | 1.61M | 3.33M | 959.24K | 146.70K |
| Interest Income | 0.00 | 1.25M | 3.22M | 719.65K | 4.25M | 3.63M | 0.00 |
| Interest Expense | 353.95K | 109.53K | 1.30M | 995.50K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 151.00 | 151.00 | 201.00 | 201.00 | 161.14K | 0.00 |
| EBITDA | -10.72M | -24.22M | -19.87M | -1.61M | 921.15K | 2.68M | -27.56K |
| EBITDA Ratio | -480.52% | -959.91% | -562.71% | -41.03% | -188.70% | 0.00% | 0.00% |
| Operating Income | -10.72M | -24.22M | -19.87M | -1.61M | -3.33M | -959.24K | -146.70K |
| Operating Income Ratio | -480.52% | -959.91% | -562.71% | -41.04% | -188.70% | 0.00% | 0.00% |
| Total Other Income/Expenses | 91.91K | 14.41K | -9.28M | 1.45M | 4.25M | 3.64M | 119.14K |
| Income Before Tax | -10.63M | -24.21M | -29.15M | -160.88K | 921.15K | 2.68M | -27.56K |
| Income Before Tax Ratio | -476.40% | -959.33% | -825.38% | -4.09% | 52.22% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 753.88K | -151.00 | 777.85K | -555.20K | 553.92K | 3.64K |
| Net Income | -10.61M | -24.96M | -29.15M | -938.73K | 1.48M | -1.34M | -31.19K |
| Net Income Ratio | -475.81% | -989.21% | -825.38% | -23.88% | 83.70% | 0.00% | 0.00% |
| EPS | -4.69 | -138.73 | -346.90 | -14.29 | 15.02 | -12.91 | -0.30 |
| EPS Diluted | -4.69 | -138.73 | -346.90 | -13.65 | 15.02 | -12.91 | -0.30 |
| Weighted Avg Shares Out | 2.26M | 179.93K | 84.02K | 65.70K | 98.26K | 104.02K | 105.00K |
| Weighted Avg Shares Out (Dil) | 2.26M | 179.93K | 84.02K | 68.78K | 98.26K | 104.02K | 105.00K |
Penny Stocks to Watch as the Fed Tightens its Monetary Policy
Ensysce Biosciences, Inc. (ENSC) CEO Dr. Lynn Kirkpatrick on Corporate Update Call (Transcript)
Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call
Short Squeeze Stocks: ISIG, RELI and 3 Others Experts Think Are Ready to Pop
Ensysce Biosciences Stock (ENSC): Why The Price Jumped
Short Squeeze Stocks: ISIG, AVCT and 5 Others Experts Think Are Ready to Pop
Best Penny Stocks To Buy This Week? 3 For Your Watch List
4 Penny Stocks Analysts Say To Buy Now & Targets Up To 117%
Ensysce Biosciences: Developing New Class Of Tamper-Proof Powerful Opioids
4 Penny Stocks That Are Trending on Reddit Right Now and Why
Source: https://incomestatements.info
Category: Stock Reports